Access
This article is part of Nature's premium content.
Published online 12 December 2007 | Nature 450, 935 (2007) | doi:10.1038/450935c
News in Brief: Business
No approval
An advisory panel to the US Food and Drug Administration has ruled that the cancer drug Avastin (bevacizumab) should not be approved for the treatment of advanced breast cancer. Shares in Genentech, the California-based biotechnology company that makes the drug, fell by $10 to $66 as news of the decision emerged last week.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.